1.89 (-%)
As of Dec 16, 2022
Source:
Kineta is a leader in the field of innate immunity and is focused on developing potentially differentiated immunotherapies. With KVA12123 in clinical development and the lead anti-CD27 agonist mAb in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.
| Country | United States |
| Headquarters | seattle, washington |
| Phone Number | ( 206 ) 378-0400 |
| Industry | manufacturing |
| CEO | Shawn Iadonato |
| Website | kinetabio.com |